What Researchers Did
The researchers reviewed pre-clinical and clinical evidence for hyperbaric oxygen therapy (HBOT) in ischemic stroke, including its potential as a neuroprotective preconditioning strategy.
What They Found
They found that HBOT showed significant pre-clinical effectiveness for acute ischemic stroke, reducing oxidative stress, inflammation, and neural apoptosis, and improving edema and oxygen perfusion. However, this pre-clinical evidence has largely failed to translate into effective clinical therapy due to inconsistencies in study protocols.
What This Means for Canadian Patients
Currently, hyperbaric oxygen therapy is not a standardized, evidence-based treatment for stroke, meaning Canadian patients should not expect it as a routine therapy. Future research into HBOT preconditioning may offer new neuroprotective strategies, but these are not yet available for clinical use.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The main limitation highlighted is the significant inconsistency in treatment protocols and design of clinical studies, which has hindered the translation of pre-clinical findings into effective evidence-based therapy.